Human Papillomavirus High Risk
Test Code
HPV HR
Associations
HPV high risk screening, cervical cancer
Methodology
DNA by Hybrid Capture® II. HPV Types 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, and 68.
CPT Codes
87621 - Papillomavirus human, amplified probe technique
Turnaround Time
3 days
Specimen Requirements
- 4.0 mL ThinPrep® PAP solution
- 2.0 mL SurePath™ Test Pack solution
- Cervical or vaginal swab in Digene collection tube
- 5 mm^3 (min. 2 mm^3) biopsy in Digene collection tube (freeze immediately)
Specimen Stability
- ThinPrep PAP solution and SurePath Test Pack solution stable at 18-25°C for 21 days
- Cervical or vaginal swab stable at 18-25°C for 2 weeks or 2-8°C for 3 weeks or frozen at -20°C for 3 months
- Biopsy stable frozen at -20°C indefinitely
Storage & Handling
- Ship ambient
- Ship frozen biopsy on dry ice
Causes for Rejection
Insufficient specimen; Digene Collection tube received without a brush
Reference Range
HPV detected/not detected
Related Content
HPV 16/18 Genotyping
Description
Used to screen women with ASC-US cervical cytology results to determine the need for referral to colposcopy.
To be used adjunctively with cervical cytology to screen women 30 years of age and older to determine the presence or absence of high risk HPV types.
References
- American Society for Colposcopy and Cervical Pathology
- Castle PE et al (2009). Five-year experience of human papillomavirus DNA and papanicolaou test cotesting. Obstet Gynecol. 113:595-600.
- Wright TC Jr et al. (2007). 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 197:346-355.
- Mayrand MH et al. (2007). Human Papillomavirus DNA versus papanicolaou screening tests for cervical cancer. NEMJ. 357:1579-88.
- Munoz N et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. NEMJ. 348:518.
- Solomon D et al. (2001). Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 93:293–9.
Trademarks
Hybrid Capture is a registered trademark of Digene Corporation.
ThinPrep is a registered trademark of Cytyc Corportation.
SurePath is a trademark of Becton, Dickinson and Company.
ThinPrep is a registered trademark of Cytyc Corportation.
SurePath is a trademark of Becton, Dickinson and Company.